{"schema_version":"secwatch.filing_event.v1","accession":"0001178913-26-002001","form_type":"8-K","ticker":"ENTXW","cik":"0001638097","company_name":"Entera Bio Ltd.","filed_at":"2026-04-03T23:59:59+00:00","discovered_at":"2026-05-14T18:02:32.638077+00:00","generated_at":"2026-05-15T07:37:18.375866+00:00","sec_items":["1.01","3.02","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Entera Bio raises $10M in private placement with BVF Partners to fund phase 3 osteoporosis study","bullets":["Gross proceeds of ~$10.0M from sale of 7,827,789 units at $1.2775/unit to funds affiliated with BVF Partners LP.","Each unit consists of one ordinary share (or pre-funded warrant) and one warrant to purchase 1.5 ordinary shares at $1.24/share.","Warrants become exercisable 6 months after closing (April 2, 2026) and expire in 5 years; cash exercise could bring additional ~$14.5M.","Net proceeds intended to support initiation of phase 3 registrational study of EB613 for postmenopausal osteoporosis and for working capital."],"urls":{"canonical":"https://secwatch.observer/filing/0001178913-26-002001","json":"https://secwatch.observer/filing/0001178913-26-002001.json","markdown":"https://secwatch.observer/filing/0001178913-26-002001.md","text":"https://secwatch.observer/filing/0001178913-26-002001.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1638097/000117891326002001/0001178913-26-002001-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1638097/000117891326002001/zk2634965.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T07:37:18.375866+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"bd554e527859621ae6e8380f998223c2c499539c","claim":"Entera Bio Ltd. issued 7,827,789 units of unit to funds affiliated with BVF Partners LP for aggregate proceeds of approximately $10.0 (or $1.2775 per Unit).","evidence_excerpt":"On April 1, 2026, Entera Bio Ltd., a company organized under the laws of the State of Israel (the “ Company ”), entered into a Securities Purchase Agreement (the “ Purchase Agreement ”) with funds affiliated with BVF Partners LP (collectively, the “ Purchaser ”), providing for the private placement (the “ Private Placement ”) to the Purchaser of an aggregate of 7,827,789 units (collectively, the “ Units ”), each Unit consisting of (i) one ordinary share, par value NIS 0.0000769 per share, of the Company (an “ Ordinary Share ”) (or, in lieu thereof, one pre-funded warrant to purchase one Ordinary Share (the “ Pre-Funded Warrants ”)) and (ii) one warrant to purchase one and a half Ordinary Shares (the “ Ordinary Share Warrant ”), for aggregate proceeds of approximately $10.0 (or $1.2775 per Unit).","evidence_source":"SEC 8-K Item 3.02/3.03","evidence_url":"https://www.sec.gov/Archives/edgar/data/1638097/000117891326002001/0001178913-26-002001-index.htm","confidence":0.9,"family_label":"Equity Issuances","details":[{"label":"Security","value":"unit"},{"label":"Shares","value":"7,827,789 units"},{"label":"Purchaser","value":"funds affiliated with BVF Partners LP"},{"label":"Consideration","value":"aggregate proceeds of approximately $10.0 (or $1.2775 per Unit)"}],"fact_type":"equity_issuance"},{"claim_id":"f624e14628949b07b937557bcfff493e6f704f75","claim":"Entera Bio Ltd. entered into Purchase Agreement with funds affiliated with BVF Partners LP valued at approximately $10.0 (effective 2026-04-01).","evidence_excerpt":"On April 1, 2026, Entera Bio Ltd., a company organized under the laws of the State of Israel (the “ Company ”), entered into a Securities Purchase Agreement (the “ Purchase Agreement ”) with funds affiliated with BVF Partners LP (collectively, the “ Purchaser ”), providing for the private placement (the “ Private Placement ”) to the Purchaser of an aggregate of 7,827,789 units (collectively, the “ Units ”), each Unit consisting of (i) one ordinary share, par value NIS 0.0000769 per share, of the Company (an “ Ordinary Share ”) (or, in lieu thereof, one pre-funded warrant to purchase one Ordinary Share (the “ Pre-Funded Warrants ”)) and (ii) one warrant to purchase one and a half Ordinary Shares (the “ Ordinary Share Warrant ”), for aggregate proceeds of approximately $10.0 (or $1.2775 per Unit).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1638097/000117891326002001/0001178913-26-002001-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"funds affiliated with BVF Partners LP"},{"label":"Value","value":"approximately $10.0"},{"label":"Effective","value":"2026-04-01"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}